News

CvilleBioHub Appoints Nikki Hastings as President, Marking New Phase of Growth and Regional Leadership

CvilleBioHub today announced that its Board of Directors has appointed Nikki Hastings as President, recognizing her leadership in building the organization into a cornerstone of Central Virginia’s life sciences ecosystem and positioning it for continued growth and influence.

The appointment comes as CvilleBioHub prepares to celebrate its 10th anniversary and marks one year since the launch of the Commonwealth BioAccelerator—milestones that underscore the organization’s accelerating impact across the region.

Since co-founding CvilleBioHub, Hastings has led the organization’s evolution from an emerging, community-focused initiative into a sought-after resource for founders, researchers, and industry partners. Under her leadership, CvilleBioHub has expanded its programming, strengthened institutional partnerships, and advanced its mission to support high-potential life sciences companies on a path to commercialization.

“This organization is growing in scope and influence and Nikki is shaping its future, not just running the day-to-day operations,” said Payam Pourtaheri, Board Chair of CvilleBioHub. “Her appointment as President reflects both the scale of what CvilleBioHub has become and the ambition of where the organization is headed. Nikki has built deep credibility with funders, institutional partners, and entrepreneurs alike, and she continues to elevate this region as a hub for life sciences innovation.”

The transition in title reflects a broader shift for CvilleBioHub as it enters a new phase defined by increased visibility, expanded partnerships, and a growing role as an ecosystem leader across Virginia and beyond.

“What started as a shared vision has grown into something far more impactful than we imagined,” said Martin Chapman, Co-Founder and Board Emeritus. “Nikki has been at the center of that growth from day one. Her leadership, persistence, and belief in what this region can become have helped turn CvilleBioHub into a true catalyst for innovation.”

As President, Hastings will continue to guide CvilleBioHub’s strategic direction, deepen its partnerships with public and private stakeholders, and expand the reach of the Commonwealth BioAccelerator to support the next generation of life sciences companies.

“I’m incredibly proud of what we’ve built together over the past decade,” said Hastings. “As we look ahead, the opportunity is even greater to strengthen this ecosystem, support exceptional founders, and ensure Virginia continues to emerge as a leader in life sciences innovation.”

Recent News

05/12/2026

Phlow Corp. Appoints Tim Mayleben Chief Executive Officer as Co-Founder Dr. Eric Edwards Transitions to Chairman Emeritus and Strategic Advisor

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Tim Mayleben has been appointed Chief Executive Officer, effective immediately. Eric Edwards, M.D., Ph.D., Phlow’s co-founder and former CEO, has transitioned to the role of Chairman Emeritus and Strategic Advisor to the CEO and Board of Directors. The leadership

05/09/2026

NIRSense Supports the US Army in the Indo-Pacific with Tissue Oxygenation Assessment for Battlefield Casualty Care at Balikatan-26

NIRSense, Inc. today announced its participation in Balikatan-26, supporting the US Army Pacific (USARPAC)’s 18th Theater Medical Command (18th TMC) as they evaluate advanced approaches to battlefield casualty assessment using portable tissue oxygen saturation (StO₂) monitoring. Balikatan, meaning “shoulder-to-shoulder,” is the longstanding U.S.-Philippine bilateral exercise designed to strengthen interoperability and regional readiness through combined operations

05/08/2026

RIVANNA Receives FDA 510(k) Clearance for Accuro XV Musculoskeletal Ultrasound Imaging System

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Accuro® XV Diagnostic Ultrasound System. The clearance marks a pivotal regulatory milestone for RIVANNA, authorizing commercial use of the Accuro XV for musculoskeletal imaging by qualified and trained healthcare professionals in hospital